Skip to main content
. 2017 Mar 15;8(26):42343–42358. doi: 10.18632/oncotarget.16216

Figure 2. Pharmacokinetics and pharmacodynamics of G1T38 in ER+ breast cancer.

Figure 2

(A) G1T38 concentration in tumor and plasma of C57BL/6 mice after a single oral 100 mg/kg dose of G1T38 (n=3 per time point). (B) RB phosphorylation levels in MCF7 tumors from mice treated with a single oral dose of vehicle or 100 mg/kg of G1T38. The western blot shown is a representation of one set of tumors from analyzed samples.